Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors
Home » Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors
2022
McKean M, Tolcher AW, Reeves JA, Chmielowski B, Shaheen MF, Beck JT, Orloff MM, Somaiah N, Van Tine BA, Drabick JJ, Spira AI, O'Byrne K, Karapetis CS, Foresto SA, Movva S, Martinez J, Li M, Winkler R, Yang D, Zhai Y. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. J Clin Oncol. [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. vol. 40 no. (suppl 16):, pp. 9517-9517, doi: 10.1200/JCO.2022.40.16_suppl.9517